source
- Expedition Therapeutics raises $115M Series B to fund phase 2 COPD trial of DPP1 inhibitorExpedition Therapeutics, backed by Sanofi, announced a $115 million Series B financing round. The round was led by General Atlantic with participation from RA Capital, Vivo Capital, and existing i…
- Pathos AI signs two cancer deals, including $2 bn contract with China's Alphamab and partnership with AstraZenecaPathos AI announced two new collaborations to expand its oncology pipeline, one with AstraZeneca and another with a subsidiary of China's Alphamab Oncology. The deal with Jiangsu Alphamab Biopharm…